5-氨基水杨酸对炎症性肠病相关性结肠癌和上皮内瘤变化学预防:Meta分析

被引：6

作者：

王承党 ^{[1
,2
]}

喻春梅 ^{[1
,2
]}

机构：

[1] 福建医科大学附属第一医院消化内科

[2] 福建医科大学消化系疾病研究室

来源：

胃肠病学和肝病学杂志 | 2013年 / 22卷 / 04期

关键词：

5-氨基水杨酸; 炎症性肠病; 溃疡性结肠炎; 克罗恩病; 结肠癌; 上皮内瘤变; 化学预防; Meta分析;

D O I：

暂无

中图分类号：

R735.35 [];

学科分类号：

摘要：

目的探讨5-氨基水杨酸(5-ASA)对炎症性肠病(IBD)相关性结肠癌(IBDACa)和上皮内瘤变(IBDADys)发生率的影响,评估5-ASA对IBDACa/Dys的化学预防作用。方法检索正式发表的关于5-ASA对IBDACa/Dys化学预防的临床研究。外文数据库包括PubMed(Medline)、EMCC、OVID、the Cochrane Library;中文数据库包括万方、维普、CNKI、谷歌学术搜索。将符合要求的文献利用统计软件RevMan统计OR值和95%CI。对研究设计类型、IBD类型进行亚组分析。结果共纳入14篇文献,其中10篇为病例对照研究,4篇为队列研究。结果显示:与未使用5-ASA相比,使用5-ASA患者的IBDACa和IBDADys发生率为50%,OR=0.50(95%CI:0.34～0.73),其中病例对照研究Meta分析结果示OR=0.30(95%CI:0.10～0.92),队列研究示OR=0.56(95%CI:0.37～0.85);使用5-ASA的溃疡性结肠炎(UC)患者发生UCCa/Dys的OR=0.45(95%CI:0.27～0.77),使用5-ASA的克罗恩病(CD)患者发生CDCa/Dys的OR=0.39(95%CI:0.16～0.97)。结论 5-ASA对IBDACa/Dys有化学预防作用。

引用

收藏

页码：348 / 353

页数：6

相关论文

共 9 条

[1]

5-Aminosalicylic Acid Interferes in the Cell Cycle of Colorectal Cancer Cells and Induces Cell Death Modes [J].

Koelink, Pim J. ;

Mieremet-Ooms, Marij A. C. ;

Corver, Willem E. ;

Wolanin, Kamila ;

Hommes, Daniel W. ;

Lamers, Cornelis B. H. W. ;

Verspaget, Hein W. .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (03) :379-389

[2]

Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine [J].

Ullman, Thomas ;

Croog, Victoria ;

Harpaz, Noam ;

Hossain, Sabera ;

Kornbluth, Asher ;

Bodian, Carol ;

Itzkowitz, Steven .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (11) :1225-1230

[3]

Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study [J].

Goldacre, Michael J. ;

Wotton, Clare J. ;

Yeates, David ;

Seagroatt, Valerie ;

Jewell, Derek .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (04) :297-304

[4]

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study [J].

Velayos, Fernando S. ;

Lofrus, Edward V., Jr. ;

Jess, Tine ;

Harmsen, W. Scott ;

Bida, John. ;

Zinsmeister, Alan R. ;

Tremaine, William J. ;

Sandborn, William J. .

GASTROENTEROLOGY, 2006, 130 (07) :1941-1949

[5]

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis [J].

Rutter, M ;

Saunders, B ;

Wilkinson, K ;

Rumbles, S ;

Schofield, G ;

Kamm, M ;

Williams, C ;

Price, A ;

Talbot, I ;

Forbes, A .

GASTROENTEROLOGY, 2004, 126 (02) :451-459

[6]

Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? [J].

Bernstein, CN ;

Blanchard, JF ;

Metge, C ;

Yogendran, M .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :2784-2788

[7]

Proximal colorectal dysplasia or cancer in ulcerative colitis.: The impact of primary sclerosing cholangitis and sulfasalazine -: Results from a 20-year surveillance study [J].

Lindberg, BU ;

Broomé, U ;

Persson, B .

DISEASES OF THE COLON & RECTUM, 2001, 44 (01) :77-83

[8]

The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis [J].

Lashner, BA ;

Provencher, KS ;

Seidner, DL ;

Knesebeck, A ;

Brzezinski, A .

GASTROENTEROLOGY, 1997, 112 (01) :29-32

[9]

Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire [J].

Moody, GA ;

Jayanthi, V ;

Probert, CSJ ;

MacKay, H ;

Mayberry, JF .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (12) :1179-1183